浙江九洲药业股份有限公司 关于全资子公司获得高新技术企业认定的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 根据全国高新技术企业认定管理工作领导小组办公室于近日发布的《对浙江 省认定机构 2025 年认定报备高新技术企业进行备案的公告》，浙江九洲药业股份 有限公司（以下简称"公司"）全资子公司浙江瑞博制药有限公司（以下简称"浙 江瑞博"）已通过高新技术企业认定，证书编号为 GR202533010708，发证时间为 2025 年 12 月 19 日，有效期为三年。 证券代码：603456 证券简称：九洲药业 公告编号：2026-001 根据国家相关规定，浙江瑞博自通过高新技术企业认定后三年内（2025 年 至 2027 年）将享受国家关于高新技术企业的税收优惠政策，即按 15%的税率缴 纳企业所得税。 特此公告。 浙江九洲药业股份有限公司 董事会 2026 年 1 月 10 日 ...

Core Viewpoint - Jiuzhou Pharmaceutical (603456) acknowledges that its stock performance is influenced by multiple factors, including market conditions and sector rotation, while actively communicating its core value to the capital market [1] Group 1 - The company has implemented a new round of share buybacks, cancellation of treasury shares, and mid-term dividends this year [1]

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：603456 证券简称：九洲药业 公告编号：2025-075 浙江九洲药业股份有限公司关于全资子公司参与投资嘉兴隆峰创业投资合伙企业（有限合伙）的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 重要内容提示： ● 投资标的名称：嘉兴隆峰创业投资合伙企业（有限合伙）（以下简称"合伙企业"） ● 投资金额：合伙企业认缴出资总额为人民币7,700万元（包含本次投资），浙江九洲药业股份有限公 司（以下简称"公司"）全资子公司浙江宏洲股权投资有限公司（以下简称"宏洲投资"）作为有限合伙人 以自有资金认缴出资额为人民币1,000万元，占合伙企业认缴出资总额的12.987%。 ● 投资方向：主要投资于新药研发、医疗器械研发项目等医药相关领域，主要包括优质的新兴医疗企 业，包括但不限于新药、创新药、医疗器械、医疗服务、诊断、生物技术、医药外包研发企业等。 ● 本次交易不构成关联交易，不构成重大资产重组。 ● 风险提示：合伙企业投资方式为股权投资，具有投资周期长、流动性低等特点， ...

证券代码：603456 证券简称：九洲药业 公告编号：2025-075 浙江九洲药业股份有限公司 关于全资子公司参与投资嘉兴隆峰创业投资合伙 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、对外投资概述 2025 年 12 月 22 日，公司全资子公司宏洲投资与石河子市隆泰股权投资管 理合伙企业（有限合伙）（以下简称"隆泰投资"）、嘉兴华锐贰号股权投资合伙 投资标的名称：嘉兴隆峰创业投资合伙企业（有限合伙）（以下简称"合 伙企业"） 投资金额：合伙企业认缴出资总额为人民币 7,700 万元（包含本次投资）， 浙江九洲药业股份有限公司（以下简称"公司"）全资子公司浙江宏洲 股权投资有限公司（以下简称"宏洲投资"）作为有限合伙人以自有资 金认缴出资额为人民币 1,000 万元，占合伙企业认缴出资总额的 12.987%。 投资方向：主要投资于新药研发、医疗器械研发项目等医药相关领域， 主要包括优质的新兴医疗企业，包括但不限于新药、创新药、医疗器械、 医疗服务、诊断、生物技术、医药外包研发企业等。 本次交易不构成关 ...

Core Viewpoint - Jiuzhou Pharmaceutical (603456.SH) announced its subsidiary Hongzhou Investment's participation in a partnership to invest in Jiaxing Longfeng Venture Capital Partnership, focusing on the pharmaceutical sector, particularly in new drug and medical device development [1] Investment Details - The total committed capital for the partnership is RMB 77 million, with Hongzhou Investment contributing RMB 10 million, representing 12.987% of the total [1] - The investment will primarily target high-quality emerging medical enterprises, including but not limited to new drugs, innovative drugs, medical devices, medical services, diagnostics, biotechnology, and pharmaceutical outsourcing research and development [1]

Core Viewpoint - Jiuzhou Pharmaceutical (603456.SH) announced that its wholly-owned subsidiary, Hongzhou Investment, plans to invest in Jiaxing Longfeng Venture Capital Partnership (Limited Partnership) with a total subscription amount of 77 million yuan, where Hongzhou Investment will contribute 10 million yuan, accounting for 12.987% of the total subscription amount [1] Group 1: Investment Details - The total subscription amount for the partnership is 77 million yuan, which includes this investment [1] - Hongzhou Investment will act as a limited partner and will contribute 10 million yuan of its own funds [1] - Hongzhou Investment's contribution represents 12.987% of the total subscription amount for the partnership [1] Group 2: Investment Focus - The partnership will primarily invest in new drug research and development, as well as medical device research projects within the pharmaceutical sector [1] - Investment targets include high-quality emerging medical enterprises, which encompass new drugs, innovative drugs, medical devices, medical services, diagnostics, biotechnology, and pharmaceutical outsourcing research and development companies [1]

Group 1 - The core point of the article is that Jiuzhou Pharmaceutical (603456.SH) announced its full subsidiary, Hongzhou Investment, plans to invest in Jiaxing Longfeng Venture Capital Partnership (Limited Partnership) [1] - The total subscribed capital of the partnership is 77 million yuan, and Hongzhou Investment will contribute 10 million yuan, accounting for 12.987% of the total subscribed capital [1] - The investment direction of the partnership focuses on new drug research and development, medical device research and development, and other pharmaceutical-related fields, including emerging medical enterprises such as new drugs, innovative drugs, medical devices, medical services, diagnostics, biotechnology, and pharmaceutical outsourcing R&D companies [1]

Key Points Summary of 九州药业 Conference Call Company Overview - 九州药业 is transitioning from generic drugs to innovative drug services, established in 1973 and entered the pharmaceutical sector in 1985. The company began its CDMO (Contract Development and Manufacturing Organization) business in 2008 and went public in 2014 [3][4]. Industry and Business Structure - The company has achieved synergy in domestic and international production through acquisitions and self-built capabilities, including the establishment of an overseas management headquarters in Singapore and R&D platforms in Japan and Germany [2][3]. - The core revenue source is the CDMO business, which generated revenue of 22.91 billion yuan in the first half of 2025, representing a year-on-year growth of 16.27% with a gross margin of 41% [2][3]. Project Pipeline and Clientele - The project pipeline has increased from 378 in 2019 to 1,214 as of the first half of 2025, including 38 commercialized products [2][3]. - Major clients include multinational corporations (MNCs) such as Novartis, Roche, and Pfizer, with Novartis accounting for over 60% of the revenue [2][5]. Financial Performance - In the first half of 2025, the raw material drug business generated revenue of 5.23 billion yuan, maintaining a gross margin of 23% despite industry competition and price declines [2][5]. - The company expects a net profit growth of around 15% over the next three years, with a revenue increase of 4.92% and a net profit increase of 18.51% year-on-year in the first three quarters of the current year [4][5]. New Business Initiatives - The establishment of the Prince Division aims to develop new molecular types such as peptides, conjugated drugs, and small nucleic acids, creating a second growth curve [2][5]. - The company is advancing commercial production capacity for these new initiatives, including three peptide conjugation platforms and capabilities for small nucleic acid research in both China and the U.S. [5]. Market Outlook and Valuation - The company is projected to maintain a net profit growth rate of approximately 15% over the next three years, with a target price of 27 yuan based on a 21x P/E ratio for 2026 [4][5]. - The current stock price reflects a P/E ratio of about 12x for 2027, indicating a favorable investment opportunity considering the rebound in raw material prices and healthy development in small molecule CDMO [5].

Group 1 - The article highlights the target price increases for several listed companies, with notable gains for Honglu Steel Structure, Jiuzhou Pharmaceutical, and Huarui Precision, showing increases of 56.76%, 48.99%, and 36.02% respectively [1][2] - On December 17, a total of 26 listed companies received recommendations from brokers, with Hubei Energy, Hefeng Co., and Zhongnan Media each receiving one recommendation [2] - The brokerage firm Qunyi Securities (Hong Kong) upgraded the rating of Tianci Materials from "Range Trading" to "Buy" on December 17 [3][4] Group 2 - On December 17, nine companies received initial coverage from brokers, including SAIC Motor and Jiuzhou Pharmaceutical, both rated "Buy" by Aijian Securities and Huachuang Securities respectively [4][5] - Other companies receiving initial coverage include Zhongke Chuangda and Kema Technology, rated "Buy" and "Increase" by Dongbei Securities [5]

Core Insights - On December 17, 2023, brokerage firms provided target prices for listed companies, with notable increases for Honglu Steel Structure (002541), Jiuzhou Pharmaceutical (603456), and Huarui Precision, showing target price increases of 56.76%, 48.99%, and 36.02% respectively, across the professional engineering, medical services, and general equipment industries [1][2]. Target Price Increases - Honglu Steel Structure (002541) received a target price of 25.27 yuan, with a target increase of 56.76% from Guotai Junan Securities [2]. - Jiuzhou Pharmaceutical (603456) has a target price of 26.64 yuan, reflecting a 48.99% increase from Huachuang Securities [2]. - Huarui Precision (688059) was assigned a target price of 110.05 yuan, indicating a 36.02% increase from Guotou Securities [2]. - Other companies with significant target price increases include Hefeng Co. (603609) at 32.58%, Tianci Materials (002709) at 27.56%, and Anfu Technology (603031) at 26.56% [2]. Rating Adjustments - On December 17, only one company had its rating upgraded, with Qunyi Securities (Hong Kong) raising Tianci Materials (002709) from "Hold" to "Buy" [3][4]. First Coverage - A total of nine companies received initial coverage on December 17, including SAIC Motor (600104) and Weilan Lithium (002245), both rated "Buy" by Aijian Securities [4][5]. - Jiuzhou Pharmaceutical (603456) was also rated "Recommended" by Huachuang Securities, while Zhongke Chuangda (300496) and Kema Technology (301611) received "Buy" and "Increase" ratings from Dongbei Securities [4][5].